Analgesia effect of premixed nitrous oxide/oxygen during the rehabilitation after total knee arthroplasty: a study protocol for a randomized controlled trial
This study will focus on exploring a fast and efficient analgesic for patients who are doing functional exercise after total knee arthroplasty. Our previous studies suggested that the prefixed nitrous oxide/oxygen mixture was an efficacious analgesic for the management of burn-dressing pain and breakthrough cancer pain. The results of this study should provide a more in-depth insight into the effects of this analgesic method. If this treatment proves successful, it could be implemented widely for patients doing functional exercise in the rehabilitation department.Trial registrationChiCTR-INR-17012891. Registered on 6 October 2017.
Publication date: Available online 4 April 2020Source: Radiation Physics and ChemistryAuthor(s): B. Juste, R. Miró, S. Morató, G. Verdú, S. Peris
Publication date: Available online 5 April 2020Source: Journal of Molecular StructureAuthor(s): T. Valarmathi, R. Premkumar, A. Milton Franklin Benial
Publication date: Available online 4 April 2020Source: Redox BiologyAuthor(s): Raúl González, María A. Rodríguez-Hernández, María Negrete, Kalina Ranguelova, Aurelie Rossin, Carmen Choya-Foces, Patricia de la Cruz-Ojeda, Antonio Miranda-Vizuete, Antonio Martínez-Ruiz, Sergio Rius-Pérez, Juan Sastre, José A. Bárcena, Anne-Odile Hueber, C. Alicia Padilla, Jordi Muntané
Publication date: Available online 4 April 2020Source: Journal de Mycologie MédicaleAuthor(s): Elie Djenontin, David Lebeaux, Hans Acikgoz, Blandine Rammaert, Marie-Elisabeth Bougnoux, Claire Rouzaud, Benjamin Bouyer, Benoit Champigneulle, Eric Dannaoui
CONCLUSIONS: This study suggests that MTC is a more immunologically active tumor that has been previously reported. Patients with advanced MTC should be screened for targetable antigens and immune checkpoints to determine their eligibility for current clinical trials. Additional studies are necessary to fully characterize the antigenic potential of MTC and may encourage the development of adoptive T cells therapies for this rare tumor. PMID: 32242507 [PubMed - as supplied by publisher]
Authors: Brignardello-Petersen R PMID: 32245571 [PubMed - as supplied by publisher]
I'm a current fellow scheduled to graduate in July. After that, I'm joining a private practice located>1000 miles away from where I'm training. Until the pandemic hit, the plan was to fly out there next month to start looking for housing. In addition to the inherent risk of travel right now, my hospital just implemented a policy that if you leave the state you have to self-quarantine for 2 weeks (and they count that as vacation time). Not sure what I'm going to do to find housing in time... Finding housing during pandemic
Publication date: Available online 4 April 2020Source: Journal of Environmental PsychologyAuthor(s): Kati Peditto, Mardelle Shepley, Naomi Sachs, Jane Mendle, Anthony Burrow
Publication date: Available online 4 April 2020Source: Aggression and Violent BehaviorAuthor(s): Scott Harcourt
Dr. Matija Snuderl, neuropathologist and molecular pathologist at New York University Langone Health, was featured ina recent article appearing inNature (March 26, 2020, Vol 579, p S14-S16). The article, which addresses the use of artificial intelligence (AI) in cancer diagnostics, opens with Dr. Snuderl experiencing a moment that many of us neuropathologists have had wherein we hesitate before signing out a case because of a feeling that something might be just a bit different about a particular specimen. That feeling prompts us to do something else (run more ancillary testing, get a consult, sleep on it and ta...